Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Rojo Arreola, Liliana ^a   Long, Thavy ^a   Asarnow, Dan ^b   Suzuki, Brian M ^a   Singh, Rahul ^a,b   Caffrey, Conor R ^a  

^a University of California at San Francisco   (United States)

^b SAN FRANCISCO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA ISOLATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE TARGETING; HELMINTHIASIS; HIGH THROUGHPUT SCREENING; IMAGE PROCESSING; LEARNING ALGORITHM; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE SURVIVAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; RNA ISOLATION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SUPPORT VECTOR MACHINE;

ANIMALS; ANTHELMINTICS; APOPTOSIS; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE KNOCKDOWN TECHNIQUES; HELMINTH PROTEINS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INHIBITORY CONCENTRATION 50; MALE; MEVALONIC ACID; MICE; MOLECULAR TARGETED THERAPY; PRAVASTATIN; RNA INTERFERENCE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SIMVASTATIN;

EID: 84900434707     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087594     Document Type: Article

References (86)

1. Lombard J, Moreira D (2011) Origins and early evolution of the mevalonate pathway of isoprenoid biosynthesis in the three domains of life. Molecular Biology and Evolution 28: 87-99.
2. Rauthan M, Pilon M (2011) The mevalonate pathway in C. elegans . Lipids in Health and Disease 10: 243.
3. Zhang FL, Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annual Review of Biochemistry 65: 241-269. (Pubitemid 26250610)
4. Miziorko HM (2011) Enzymes of the mevalonate pathway of isoprenoid biosynthesis. Archives of Biochemistry and Biophysics 505: 131-143.
5. Thurnher M, Nussbaumer O, Gruenbacher G (2012) Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clinical Cancer Research 18: 3524-3531.
6. Edwards PA, Ericsson J (1999) Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annual Review of Biochemistry 68: 157-185. (Pubitemid 29449190)
7. Endo A (1985) Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. Journal of Medicinal Chemistry 28: 401-405.
8. Endo A (1992) The discovery and development of HMG-CoA reductase inhibitors. Journal of Lipid Research 33: 1569-1582.
9. Manzoni M, Rollini M (2002) Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Applied Microbiology and Biotechnology 58: 555-564. (Pubitemid 34299219)
10. Barrios-González J, Miranda R (2010) Biotechnological production and applications of statins. Applied Microbiology and Biotechnology 85: 869-883.
11. Jain MK, Ridker PM (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nature Reviews Drug Discovery 4: 977-987.
12. Greenwood J, Steinman L, Zamvil SS (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nature Reviews Immunology 6: 358-370.
13. Demierre M-F, Higgins PDR, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nature Reviews Cancer 5: 930-942. (Pubitemid 41766782)
14. Corcos L, Le Jossic-Corcos C (2013) Statins: Perspectives in cancer therapeutics. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 45: 795-802.
15. Andersson M, Low P, Bakhiet M (1996) Lovastatin inhibits interferon-gammainduced Trypanosoma brucei brucei proliferation: evidence for mevalonate pathway involvement. Journal of Interferon & Cytokine Research 16: 435-439.
16. Urbina JA, Lazardi K, Marchan E, Visbal G, Aguirre T, et al. (1993) Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrobial Agents and Chemotherapy 37: 580-591. (Pubitemid 23072606)
17. Montalvetti A, Peña-Díaz J, Hurtado R, Ruiz-Pérez LM, González-Pacanowska D (2000) Characterization and regulation of Leishmania major 3-hydroxy-3-methylglutaryl-CoA reductase. The Biochemical Journal 349: 27-34. (Pubitemid 30440161)
18. Eastman RT, Buckner FS, Yokoyama K, Gelb MH, Van Voorhis WC (2006) Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. Journal of Lipid Research 47: 233-240.
19. Pradines B, Torrentino-Madamet M, Fontaine A, Henry M, Baret E, et al. (2007) Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrobial Agents and Chemotherapy 51: 2654-2655. (Pubitemid 47047361)
20. Parquet V, Henry M, Wurtz N, Dormoi J, Briolant S, et al. (2010) Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum. Malaria Journal 9: 139.
21. Rajkovic A, Simonsen JN, Davis RE, Rottman FM (1989) Molecular cloning and sequence analysis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase from the human parasite Schistosoma mansoni. Proceedings of the National Academy of Sciences of the United States of America 86: 8217-8221. (Pubitemid 19286030)
22. Chen G-Z, Bennett JL (1993) Characterization of mevalonate-labeled lipids isolated from parasite proteins in Schistosoma mansoni . Molecular and Biochemical Parasitology 59: 287-292.
23. Brooker S, Hotez PJ, Bundy DAP (2010) The global atlas of helminth infection: mapping the way forward in neglected tropical disease control. PLoS Neglected Tropical Diseases 4: e779.
24. Caffrey CR, Secor WE (2011) Schistosomiasis: from drug deployment to drug development. Current Opinion in Infectious Diseases 24: 410-417.
25. Goldstein JL, Brown MS (1984) Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. Journal of Lipid Research 25: 1450-1461. (Pubitemid 15169461)
26. Roitelman J, Olender EH, Bar-Nun S, Dunn WA, Simoni RD (1992) Immunological evidence for eight spans in the membrane domain of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for enzyme degradation in the endoplasmic reticulum. The Journal of Cell Biology 117: 959-973.
27. Istvan ES, Palnitkar M, Buchanan SK, Deisenhofer J (2000) Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. The EMBO Journal 19: 819-830. (Pubitemid 30119808)
28. Burg JS, Espenshade PJ (2011) Regulation of HMG-CoA reductase in mammals and yeast. Progress in Lipid Research 50: 403-410.
29. Chen G-Z, Foster L, Bennett JL (1991) Purification and characterization of 3-hydroxymethylglutaryl-coenzyme a reductase of Schistosoma mansoni: regulation of parasite enzyme activity differs from mammalian host. Experimental Parasitology 73: 82-92.
30. Meyer F, Meyer H, Bueding E (1970) Lipid metabolism in the parasitic and free-living flatworms, Schistosoma mansoni and Dugesia dorotocephala. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 210: 257-266.
31. Kurzchalia TV, Ward S (2003) Why do worms need cholesterol? Nature Cell Biology 5: 684-688. (Pubitemid 36986768)
32. Vandewaa EA, Mills G, Chen GZ, Foster LA, Bennett JL (1989) Physiological role of HMG-CoA reductase in regulating egg production by Schistosoma mansoni. American Journal of Physiology 257: R618-R625.
33. Araujo N, Kohn A, Oliveira AA, Katz N (2002) Schistosoma mansoni: the action of lovastatin on the murine model. Revista da Sociedade Brasileira de Medicina Tropical 35: 35-38. (Pubitemid 34165668)
34. Chen G-Z, Foster L, Bennett JL (1990) Antischistosomal action of mevinolin: evidence that 3-hydroxy-methylglutaryl-coenzyme a reductase activity in Schistosoma mansoni is vital for parasite survival. Naunyn-Schmiedeberg's Archives of Pharmacology 342: 477-482. (Pubitemid 20284133)
35. Abdulla M-H, Ruelas DS, Wolff B, Snedecor J, Lim K-C, et al. (2009) Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Neglected Tropical Diseases 3: e478.
36. Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, et al. (2009) Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 136: 1825-1835.
37. Štefanic S, Dvořák J, Horn M, Braschi S, Sojka D, et al. (2010) RNA Interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening. PLoS Neglected Tropical Diseases 4: e850.
38. Basch PF (1981) Cultivation of Schistosoma mansoni in vitro. I. Establishment of cultures from cercariae and development until pairing. The Journal of Parasitology 67: 179-185.
39. Andrews P (1985) Praziquantel: mechanisms of anti-schistosomal activity. Pharmacology and Therapeutics 29: 129-156.
40. Asarnow DE, Singh R (2013) Segmenting the etiological agent of schistosomiasis for high-content screening. IEEE Transactions on Medical Imaging 32: 1007-1018.
41. Paveley RA, Mansour NR, Hallyburton I, Bleicher LS, Benn AE, et al. (2012) Whole organism high-content screening by label-free, image-based bayesian classification for parasitic diseases. PLoS Neglected Tropical Diseases 6: e1762.
42. Singh R, Pittas M, Heskia I, Xu F, McKerrow JH, et al. (2009) Automated image-based phenotypic screening for high-throughput drug discovery. IEEE Symposium on Computer-Based Medical Systems (CBMS) 2009, 1-8.
43. Lee H, Moody-Davis A, Saha U, Suzuki BM, Asarnow D, et al. (2012) Quantification and clustering of phenotypic screening data using time-series analysis for chemotherapy of schistosomiasis. BMC Genomics 13 Suppl 1: S4.
44. Hu M-K (1962) Visual pattern recognition by moment invariants. IEEE Transactions on Information Theory/Professional Technical Group on Information Theory 8: 179-187.
45. Haralick RM, Shanmugam K, Dinstein IH (1973) Textural features for image classification. IEEE Transactions on Systems, Man, and Cybernetics SMC-3: 610-621.
46. Manjunath BS, Ma WY (1996) Texture features for browsing and retrieval of image data. IEEE Transactions on Pattern Analysis and Machine Intelligence 18: 837-842. (Pubitemid 126772825)
47. Cortes C, Vapnik V (1995) Support-vector networks. Machine Learning 20: 273-297.
48. Platt JC (1998) Sequential minimal optimization: a fast algorithm for training support vector machines. Microsoft Research. 21 p.
49. Abdulla M-H, Lim K-C, Sajid M, McKerrow JH, Caffrey CR (2007) Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Medicine 4: e14.
50. Rozen S, Skaletsky H (1999) Primer3 on the WWW for general users and for biologist programmers. In: Misener S, Krawetz S, editors. Bioinformatics Methods and Protocols. pp. 365-386.
51. Nolan T, Hands RE, Bustin SA (2006) Quantification of mRNA using real-time RT-PCR. Nature Protocols 1: 1559-1582.
52. Jolly E, Chin C-S, Miller S, Bahgat M, Lim KC, et al. (2007) Gene expression patterns during adaptation of a helminth parasite to different environmental niches. Genome Biology 8: R65.
53. Dvořák J, Mashiyama ST, Sajid M, Braschi S, Delcroix M, et al. (2009) SmCL3, a gastrodermal cysteine protease of the human blood fluke Schistosoma mansoni. PLoS Neglected Tropical Diseases 3: e449.
54. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 22DDCT method. Methods: a companion to Methods in Enzymology 25: 402-408.
55. Dubois F, Caby S, Oger F, Cosseau C, Capron M, et al. (2009) Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni . Molecular and Biochemical Parasitology 168: 7-15.
56. Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 45: 89-118. (Pubitemid 40261799)
57. Almuti K, Rimawi R, Spevack D, Ostfeld RJ (2006) Effects of statins beyond lipid lowering: Potential for clinical benefits. International Journal of Cardiology 109: 7-15.
58. Wang C-Y, Liu P-Y, Liao JK (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends in Molecular Medicine 14: 37-44.
59. Henneman L, van Cruchten AG, Kulik W, Waterham HR (2011) Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC- MS/MS. Biochimica et Biophysica Acta 1811: 227-233.
60. Soliman MFM, Ibrahim MM (2005) Antischistosomal action of atorvastatin alone and concurrently with medroxyprogesterone acetate on Schistosoma haematobium harboured in hamster: surface ultrastructure and parasitological study. Acta Tropica 93: 1-9. (Pubitemid 39611349)
61. Crowther GJ, Shanmugam D, Carmona SJ, Doyle MA, Hertz-Fowler C, et al. (2010) Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Neglected Tropical Diseases 4: e804.
62. Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, et al. (2009) The genome of the blood fluke Schistosoma mansoni. Nature 460: 352-358.
63. Han H, Peng J, Gobert GN, Hong Y, Zhang M, et al. (2013) Apoptosis phenomenon in the schistosomulum and adult worm life cycle stages of Schistosoma japonicum . Parasitology International 62: 100-108.
64. Clendening JW, Pandyra A, Boutros PC, Ghamrasni SE, Khosravi F, et al. (2010) Dysregulation of the mevalonate pathway promotes transformation. Proceedings of the National Academy of Sciences of the United States of America 107: 15051-15056.
65. Chang H-L, Chen C-Y, Hsu Y-F, Kuo W-S, Ou G, et al. (2013) Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade. Biochimica et Biophysica Acta (BBA) - General Subjects 1830: 4053-4064.
66. Osman A, Niles EG, LoVerde PT (1999) Characterization of the Ras homologue of Schistosoma mansoni. Molecular and Biochemical Parasitology 100: 27-41. (Pubitemid 29206670)
67. Vermeire JJ, Osman A, LoVerde PT, Williams DL (2003) Characterisation of a Rho homologue of Schistosoma mansoni. International Journal for Parasitology 33: 721-731. (Pubitemid 36695025)
68. Quack T, Knobloch J, Beckmann S, Vicogne J, Dissous C, et al. (2009) The Formin-homology rotein SmDia interacts with the Src kinase SmTK and the GTPase SmRho1 in the gonads of Schistosoma mansoni. PloS ONE 4: e6998.
69. Joshi H, Fakes MG, Serajuddin ATM. (1999) Differentiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors by their relative lipophilicity. Pharmacy and Pharmacology Communications 5: 269-271. (Pubitemid 29245825)
70. Mo H, Elson CE (2004) Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Experimental Biology and Medicine/Society for Experimental Biology and Medicine 229: 567-585.
71. Appels NMGM, Beijnen JH, Schellens JHM (2005) Development of farnesyl transferase inhibitors: a review. The Oncologist 10: 565-578. (Pubitemid 41429120)
72. Berndt N, Hamilton AD, Sebti SdM (2011) Targeting protein prenylation for cancer therapy. Nature Reviews Cancer 11: 775-791.
73. Berndt N, Sebti SM (2011) Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors. Nature Protocols 6: 1775-1791.
74. Coxon FP (2008) An update on the pharmacology of bisphosphonates and analogues with lower bone affinity. IBMS BoneKEy 5: 357-369.
75. Wasko BM, Dudakovic A, Hohl RJ (2011) Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. The Journal of Pharmacology and Experimental Therapeutics 337: 540-546.
76. Montalvetti A, Bailey BN, Martin MB, Severin GW, Oldfield E, et al. (2001) Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. The Journal of Biological Chemistry 276: 33930-33937.
77. Garzoni LR, Caldera A, Meirelles MdNL, Castro SLd, Docampo R, et al. (2004) Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. International Journal of Antimicrobial Agents 23: 273-285. (Pubitemid 38283597)
78. Ochocki JD, Distefano MD (2013) Prenyltransferase inhibitors: treating human ailments from cancer to parasitic infections. Medicinal Chemistry Communications 10.1039/C2MD20299A
79. Olliaro P, Seiler J, Kuesel A, Horton J, Clark JN, et al. (2011) Potential drug development candidates for human soil-transmitted helminthiases. PLoS Neglected Tropical Diseases 5: e1138.
80. de Hostos EL, Nguyen T (2012) Anthelmintic drugs: tools and shortcuts for the long road from discovery to product. In: Caffrey CR, editor. Parasitic Helminths: Genes, Screens, Drugs and Vaccines. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. pp. 217-232.
81. Gönnert R, Andrews P (1977) Praziquantel, a new broad-spectrum antischistosomal agent. Zeitschrift für Parasitenkunde 52: 129-150. (Pubitemid 8155044)
82. Bellosta S, Paoletti R, Corsini A (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109: III-50-III-57.
83. Holstein S, Knapp H, Clamon G, Murry D, Hohl R (2006) Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemotherapy and Pharmacology 57: 155-164. (Pubitemid 41779834)
84. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ (1986) Schistosoma mansoni: chemotherapy of infections of different ages. Experimental Parasitology 61: 294-303. (Pubitemid 16069841)
85. Taylor MJ, Hoerauf A, Bockarie M (2010) Lymphatic filariasis and onchocerciasis. Lancet 376: 1175-1185.
86. Tamarozzi F, Tendongfor N, Enyong P, Esum M, Faragher B, et al. (2012) Long term impact of large scale community-directed delivery of doxycycline for the treatment of onchocerciasis. Parasites & Vectors 5: 53.